FindMyKOL
Clinical trialNCT00879710CompletedInterventional

Effect of Diabetes Mellitus on Cholesterol Metabolism

NCT00879710 is an interventional trial sponsored by Medical College of Wisconsin. As of 21 Nov 2026, it is completed. It studies Simvastatin or ezetimibe in Hypercholesterolemia, Type 1 Diabetes Mellitus and 1 more condition. The registry lists an enrollment of 57 participants at 1 site in 1 country. The registry lists a start date of 31 Aug 2008 and a primary completion date of 31 Jul 2013.

SponsorMedical College of Wisconsin →Enrollment57HypercholesterolemiaType 1 Diabetes MellitusType 2 Diabetes Mellitus
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT00879710
FieldValue
Registry IDNCT00879710
StatusCompleted
Study typeInterventional trial
Lead sponsorMedical College of Wisconsin
Enrollment57
Registered sites1
Countries1
ConditionsHypercholesterolemia, Type 1 Diabetes Mellitus and Type 2 Diabetes Mellitus
DrugsSimvastatin or ezetimibe
Start31 Aug 2008
Primary completion31 Jul 2013
Study completion31 Jul 2013
Last update posted29 Jul 2020

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

HMG CoA reductase inhibitors (statins) are commonly used to treat high cholesterol (HC) in both type 1 and type 2 diabetes mellitus (DM). Several studies have shown benefits of statin among patients of type 2 DM, however, no such data is available for patients with type 1 DM. It is known from studies on cholesterol metabolism using surrogate markers that patients with type 1 DM have higher cholesterol absorption compared to normals and those with type 2 DM have higher cholesterol synthesis. Since statins inhibit synthesis, patients with type 1 DM may not have a good response and may respond better to cholesterol absorption inhibitors. The purpose of this study is to determine the cholesterol lowering effects of cholesterol absorption inhibitors and cholesterol synthesis inhibitors in subjects with type 1 and type 2 diabetes mellitus.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Wisconsin, United States1 site
  • Medical College of Wisconsin /froedtert Hospital

    Milwaukee

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsin: 1 siteWI1MichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Simvastatin or ezetimibe
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT00879710

Each answer restates registry values shown on this page.

What is NCT00879710?

NCT00879710 is an interventional trial sponsored by Medical College of Wisconsin. It studies Simvastatin or ezetimibe in Hypercholesterolemia, Type 1 Diabetes Mellitus and 1 more condition.

Who leads NCT00879710?

The registry names Shailendra B Patel, MD, PhD (principal investigator, Medical College of Wisconsin) and Srividya Kidambi, MD (principal investigator, Medical College of Wisconsin) as overall officials.

Where does NCT00879710 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT00879710 study?

The registered drug and biological interventions are Simvastatin or ezetimibe.

When did NCT00879710 end?

The registry lists a primary completion date of 31 Jul 2013 and a study completion date of 31 Jul 2013. The sponsor last updated the record on 29 Jul 2020.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.